Q-omics provides the consensus-scored MTFR2P2 profile across patient tissues and cancer cell-line models. MTFR2P2 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MTFR2P2 is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, MTFR2P2 RNA expression shows 9,765 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LUSC, and LSCC as cancer lineages where MTFR2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTFR2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTFR2P2 survival associations across molecular data types. MTFR2P2 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTFR2P2 RNA expression–survival associations across cancer types. High MTFR2P2 expression shows unfavorable associations in UVM, DLBC and READ, but favorable associations in LUSC, LGG and CESC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MTFR2P2 RNA expression.
This table summarizes MTFR2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MTFR2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTFR2P2 shows higher tumor expression in LUSC and KIRC. The LUSC box plot shows higher MTFR2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.204, t-test p < 0.001).
This table shows molecular features associated with MTFR2P2 in patient tissues and cancer cell lines. In patient samples, MTFR2P2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
